Director Robert Profusek filed a Form 4 with the SEC on November 9, 2026, reporting the acquisition of 2,813 restricted stock units of CTS Corp on November 5, 2026, at no cost.

Key Highlights

  • Transaction: Robert Profusek acquired 2,813 shares of Common Stock in the form of restricted stock units (transaction code A) on November 5, 2026, at a price of $0.
  • Vesting terms: According to the filing, the restricted stock units vest 100% on the first anniversary of the grant date, contingent upon the recipient's continued service as a director through the vesting date.
  • Direct holdings after transaction: Profusek directly beneficially owns 104,555 shares of Common Stock following the reported transaction.
  • Indirect holdings: Profusek also holds 1,800 shares of Common Stock indirectly, by spouse.
  • Relationship to issuer: The filing identifies Profusek as a Director of CTS Corp, listed on NYSE:CTS.

Profusek RSU Grant Details and Beneficial Ownership at CTS Corp

According to the Form 4 filed on November 9, 2026, director Robert Profusek received 2,813 restricted stock units of CTS Corp (NYSE:CTS) common stock on November 5, 2026. The transaction was coded "A" (acquired) and the price recorded was $0, consistent with an award grant rather than a market purchase. The filing was signed by Debra S. Rouse as attorney-in-fact for Robert Profusek.

The filing discloses that the restricted stock units "vest 100% on the first anniversary of the grant date, contingent upon the recipient's continued service as a director through the vesting date." No derivative securities were reported in Table II of the filing.

Following the reported transaction, Profusek's direct beneficial ownership of CTS Corp Common Stock stands at 104,555 shares, according to the filing. An additional 1,800 shares are held indirectly by his spouse. The form was filed by one reporting person and is not indicated as an amendment to a prior filing.

What Was Disclosed

The filing reports a grant of 2,813 restricted stock units to CTS Corp director Robert Profusek on November 5, 2026, at no cost, with vesting contingent on continued board service through the first anniversary of the grant date. Post-transaction direct ownership is reported as 104,555 shares.